In particular, several splicing factors, such as hnRNP A2/B1, SRSF1, and SRSF6, have been shown to act as driver oncogenes in some cancers [83–86]; thus, they have gained attention as promising targets for cancer therapy. Here, SRSF1 is linked to cancer.